Heron Therapeutics Initiates Phase 1 Clinical Study of HTX-011 for the Treatment of Post-Operative Pain
02/11/2015
|
-Phase 1 single ascending-dose study in healthy volunteers to be completed in first quarter
-Phase 1b/2 studies in surgical patients to start in second quarter
The single-ascending dose, placebo-controlled study in healthy volunteers will evaluate safety, pharmacokinetics, and pharmacodynamics of the anesthetic effects of the product. HTX-011 has previously been shown to significantly reduce pain in a validated animal model for up to 72 hours following surgery.
“We look forward to rapidly completing our Phase 1 study of HTX-011, the
lead product candidate in our post-surgical pain program, and expect to
report initial results before the end of the first quarter of 2015,”
commented Barry D. Quart, Pharm.D., Chief Executive Officer of
About
Forward Looking Statements
This news release contains "forward-looking statements" as defined by
the Private Securities Litigation Reform Act of 1995. Heron cautions
readers that forward-looking statements are subject to certain risks and
uncertainties that could cause actual results to differ materially.
These risks and uncertainties include those associated with the timing
of completion of the HEC study, and the results thereof, and the NDA
resubmission for SUSTOL, potential regulatory approval of SUSTOL and the
timing for such approval, if approved at all; risks relating to progress
in research and development of HTX-019, HTX-011, HTX-003 and our other
product candidate programs, including the timing of planned toxicology
and clinical studies; the risk that safety and efficacy data from our
clinical studies may not warrant further development of our product
candidates, risks related to the launch and acceptance of new products
generally; risks related to our financial position and our ability to
raise additional capital to fund operations if necessary or to pursue
additional business opportunities; risks related to strategic business
alliances we may pursue or the potential acquisition of other products
or technologies and other risks and uncertainties identified in the
Company's filings with the
Source:
Heron Therapeutics, Inc.
Investor Relations Contact:
Jennifer
Capuzelo, 858-703-6063
Sr. Manager, Investor Relations
jcapuzelo@herontx.com
or
Corporate
Contact:
Barry D. Quart, 650-366-2626
Pharm D., Chief
Executive Officer